{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T19:24:36Z","timestamp":1792697076035,"version":"4.5.0"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T00:00:00Z","timestamp":1771977600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007956","name":"Nanjing University of Traditional Chinese Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007956","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010618","name":"Guangzhou University of Chinese Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010618","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.intimp.2026.116439","type":"journal-article","created":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T17:50:24Z","timestamp":1772128224000},"page":"116439","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["CXCL9 as a key feature for deep learning-based immune subtyping and prediction of immune checkpoint blockade response in triple-negative breast cancer"],"prefix":"10.1016","volume":"175","author":[{"given":"Juan","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biao","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingwu","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yizhen","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanmei","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongming","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suchen","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linxin","family":"Teng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengyan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2026.116439_bb0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.fct.2022.113205","article-title":"Carnosic acid attenuates doxorubicin-induced cardiotoxicity by decreasing oxidative stress and its concomitant pathological consequences","volume":"166","author":"Manna","year":"2022","journal-title":"Food Chem. Toxicol."},{"issue":"2","key":"10.1016\/j.intimp.2026.116439_bb0010","doi-asserted-by":"crossref","first-page":"120","DOI":"10.5306\/wjco.v8.i2.120","article-title":"Targeted therapies in breast cancer: new challenges to fight against resistance","volume":"8","author":"Masoud","year":"2017","journal-title":"World J. Clin Oncol."},{"issue":"1","key":"10.1016\/j.intimp.2026.116439_bb0015","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41523-023-00508-3","article-title":"Immunotherapy in breast cancer: an overview of current strategies and perspectives","volume":"9","author":"Debien","year":"2023","journal-title":"NPJ Breast Cancer"},{"issue":"4","key":"10.1016\/j.intimp.2026.116439_bb0020","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1158\/2326-6066.CIR-13-0127","article-title":"PD-L1 expression in triple-negative breast cancer","volume":"2","author":"Mittendorf","year":"2014","journal-title":"Cancer Immunol. Res."},{"issue":"3","key":"10.1016\/j.intimp.2026.116439_bb0025","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1093\/annonc\/mdy517","article-title":"Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort a of the phase II KEYNOTE-086 study","volume":"30","author":"Adams","year":"2019","journal-title":"Ann. Oncol."},{"issue":"11","key":"10.1016\/j.intimp.2026.116439_bb0030","doi-asserted-by":"crossref","first-page":"3061","DOI":"10.1158\/1078-0432.CCR-20-4726","article-title":"Eribulin plus Pembrolizumab in patients with metastatic triple-negative breast Cancer (ENHANCE 1): a phase Ib\/II study","volume":"27","author":"Tolaney","year":"2021","journal-title":"Clin. Cancer Res."},{"issue":"4","key":"10.1016\/j.intimp.2026.116439_bb0035","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/S1470-2045(20)30754-3","article-title":"Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial","volume":"22","author":"Winer","year":"2021","journal-title":"Lancet Oncol."},{"issue":"10","key":"10.1016\/j.intimp.2026.116439_bb0040","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1001\/jamaoncol.2020.3524","article-title":"Effect of Eribulin with or without Pembrolizumab on progression-free survival for patients with hormone receptor-positive, ERBB2-negative metastatic breast Cancer: a randomized clinical trial","volume":"6","author":"Tolaney","year":"2020","journal-title":"JAMA Oncol."},{"issue":"1","key":"10.1016\/j.intimp.2026.116439_bb0045","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41523-021-00219-7","article-title":"Neoadjuvant durvalumab plus weekly nab-paclitaxel and dose-dense doxorubicin\/cyclophosphamide in triple-negative breast cancer","volume":"7","author":"Foldi","year":"2021","journal-title":"NPJ Breast Cancer"},{"key":"10.1016\/j.intimp.2026.116439_bb0050","doi-asserted-by":"crossref","unstructured":"Bachelot Thomas, Filleron Thomas, Bieche Ivan, et al. Durvalumab compared to maintenance chemotherapy in metastatic BREAST cancer: the randomized phase II SAFIR02-BREAST IMMUNO trial. Nat. Med., 2021. 27(2): p. 250\u2013255.","DOI":"10.1038\/s41591-020-01189-2"},{"issue":"6","key":"10.1016\/j.intimp.2026.116439_bb0055","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/s41571-021-00473-5","article-title":"PD-L1 as a biomarker of response to immune-checkpoint inhibitors","volume":"18","author":"Doroshow","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.intimp.2026.116439_bb0060","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1172\/JCI96313","article-title":"Spatially distinct tumor immune microenvironments stratify triple-negative breast cancers","volume":"129","author":"Gruosso","year":"2019","journal-title":"J. Clin. Invest."},{"issue":"3","key":"10.1016\/j.intimp.2026.116439_bb0065","doi-asserted-by":"crossref","first-page":"e175","DOI":"10.1016\/S1470-2045(19)30026-9","article-title":"Immunotherapy and targeted therapy combinations in metastatic breast cancer","volume":"20","author":"Esteva","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.intimp.2026.116439_bb0070","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1038\/s41523-020-00197-2","article-title":"Practical classification of triple-negative breast cancer: intratumoral heterogeneity, mechanisms of drug resistance, and novel therapies","volume":"6","author":"Marra","year":"2020","journal-title":"NPJ Breast Cancer"},{"issue":"3","key":"10.1016\/j.intimp.2026.116439_bb0075","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.ccell.2019.02.001","article-title":"Genomic and transcriptomic landscape of triple-negative breast cancers: subtypes and treatment strategies","volume":"35","author":"Jiang","year":"2019","journal-title":"Cancer Cell"},{"key":"10.1016\/j.intimp.2026.116439_bb0080","doi-asserted-by":"crossref","unstructured":"Lehmann Brian D., Bauer Joshua A., Chen Xi, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J. Clin. Invest., 2011. 121(7): p. 2750\u20132767.","DOI":"10.1172\/JCI45014"},{"key":"10.1016\/j.intimp.2026.116439_bb0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.104683","article-title":"Tumor microenvironment: challenges and opportunities in targeting metastasis of triple negative breast cancer","volume":"153","author":"Deepak","year":"2020","journal-title":"Pharmacol. Res."},{"issue":"1","key":"10.1016\/j.intimp.2026.116439_bb0090","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1093\/nar\/30.1.207","article-title":"Gene expression omnibus: NCBI gene expression and hybridization array data repository","volume":"30","author":"Ron","year":"2002","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.intimp.2026.116439_bb0095","doi-asserted-by":"crossref","unstructured":"Weinstein John N., Collisson Eric A., Mills Gordon B., et al. The Cancer genome atlas Pan-Cancer analysis project. Nat. Genet., 2013. 45(10): p. 1113\u20131120.","DOI":"10.1038\/ng.2764"},{"issue":"6","key":"10.1016\/j.intimp.2026.116439_bb0100","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1038\/ng.2653","article-title":"The genotype-tissue expression (GTEx) project","volume":"45","year":"2013","journal-title":"Nat. Genet."},{"issue":"1","key":"10.1016\/j.intimp.2026.116439_bb0105","first-page":"118","article-title":"Adjusting batch effects in microarray expression data using empirical Bayes methods","volume":"8","author":"Evan","year":"2006","journal-title":"Biostatistics (Oxford, England)"},{"key":"10.1016\/j.intimp.2026.116439_bb0110","doi-asserted-by":"crossref","unstructured":"Newman Aaron M., Liu Chih Long, Green Michael R., et al. Robust enumeration of cell subsets from tissue expression profiles. Nat. Methods, 2015. 12(5): p. 453\u2013457.","DOI":"10.1038\/nmeth.3337"},{"issue":"1","key":"10.1016\/j.intimp.2026.116439_bb0115","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13073-019-0638-6","article-title":"Molecular and pharmacological modulators of the tumor immune contexture revealed by deconvolution of RNA-seq data","volume":"11","author":"Finotello","year":"2019","journal-title":"Genome Med."},{"issue":"1","key":"10.1016\/j.intimp.2026.116439_bb0120","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1186\/s13059-017-1349-1","article-title":"XCell: digitally portraying the tissue cellular heterogeneity landscape","volume":"18","author":"Aran","year":"2017","journal-title":"Genome Biol."},{"issue":"1","key":"10.1016\/j.intimp.2026.116439_bb0125","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/s40364-023-00536-y","article-title":"Exploring the feasibility of using long-term stored newborn dried blood spots to identify metabolic features for congenital heart disease screening","volume":"11","author":"Ceresnak","year":"2023","journal-title":"Biomark. Res."},{"key":"10.1016\/j.intimp.2026.116439_bb0130","doi-asserted-by":"crossref","unstructured":"Tang Qiming, Huang Yuhui, Ni Xiaoxiang, et al. Increased \u03b1-ketoglutarate links the C3-C4 intermediate state to C4 photosynthesis in the genus Flaveria. Plant Physiol., 2024. 195(1): p. 291\u2013305.","DOI":"10.1093\/plphys\/kiae077"},{"key":"10.1016\/j.intimp.2026.116439_bb0135","doi-asserted-by":"crossref","unstructured":"Sadria Mehrshad, Layton Anita, Goyal Sidhartha, et al. Fatecode enables cell fate regulator prediction using classification-supervised autoencoder perturbation. Cell Reports Methods, 2024. 4(7): p. 100819.","DOI":"10.1016\/j.crmeth.2024.100819"},{"key":"10.1016\/j.intimp.2026.116439_bb0140","doi-asserted-by":"crossref","unstructured":"Zhang Qihuang, Jiang Shunzhou, Schroeder Amelia, et al. Leveraging spatial transcriptomics data to recover cell locations in single-cell RNA-seq with CeLEry. Nat. Commun., 2023. 14(1): p. 4050.","DOI":"10.1038\/s41467-023-39895-3"},{"key":"10.1016\/j.intimp.2026.116439_bb0145","doi-asserted-by":"crossref","unstructured":"Zhang Xinyi, Wang Xiao, Shivashankar G. V., et al. Graph-based autoencoder integrates spatial transcriptomics with chromatin images and identifies joint biomarkers for Alzheimer's disease. Nature Communications, 2022. 13(1): p. 7480.","DOI":"10.1038\/s41467-022-35233-1"},{"key":"10.1016\/j.intimp.2026.116439_bb0150","doi-asserted-by":"crossref","unstructured":"Bader Jackie E., Wolf Melissa M., Lupica-Tondo Gian Luca, et al. Obesity induces PD-1 on macrophages to suppress anti-tumour immunity. Nature, 2024. 630(8018): p. 968\u2013975.","DOI":"10.1038\/s41586-024-07529-3"},{"key":"10.1016\/j.intimp.2026.116439_bb0155","doi-asserted-by":"crossref","unstructured":"Wang Ying, Tiruthani Karthik, Li Sirui, et al. mRNA delivery of a bispecific single-domain antibody to polarize tumor-associated macrophages and synergize immunotherapy against liver malignancies. Advanced Materials (Deerfield Beach, Fla.), 2021. vol. 33(23): p. e2007603.","DOI":"10.1002\/adma.202007603"},{"key":"10.1016\/j.intimp.2026.116439_bb0160","doi-asserted-by":"crossref","unstructured":"Zhang Yuanyuan, Chen Hongyan, Mo Hongnan, et al. Distinct cellular mechanisms underlie chemotherapies and PD-L1 blockade combinations in triple-negative breast cancer. Cancer Cell, 2025. 43(3).","DOI":"10.1016\/j.ccell.2025.01.007"},{"key":"10.1016\/j.intimp.2026.116439_bb0165","doi-asserted-by":"crossref","unstructured":"Jiang Qiuyu, Chen Zhixue, Meng Fansheng, et al. CD36-BATF2\\MYB axis predicts anti-PD-1 immunotherapy response in gastric cancer. Int. J. Biol. Sci., 2023. 19(14): p. 4476\u20134492.","DOI":"10.7150\/ijbs.87635"},{"key":"10.1016\/j.intimp.2026.116439_bb0170","doi-asserted-by":"crossref","unstructured":"Nahar Saifun, Huang Yue, Nagy Bethany A., et al. Regression and eradication of triple-negative breast carcinoma in 4T1 mouse model by combination immunotherapies. Cancers, 2023. 15(8).","DOI":"10.3390\/cancers15082366"},{"issue":"5","key":"10.1016\/j.intimp.2026.116439_bb0175","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.annonc.2021.02.006","article-title":"High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types","volume":"32","author":"McGrail","year":"2021","journal-title":"Ann. Oncol.: Off. J. Eur. Soc. For Med. Oncol."},{"issue":"7","key":"10.1016\/j.intimp.2026.116439_bb0180","doi-asserted-by":"crossref","first-page":"102200","DOI":"10.1016\/j.xcrm.2025.102200","article-title":"Interferon-responsive HEVs drive tumor tertiary lymphoid structure formation and predict immunotherapy response in nasopharyngeal carcinoma","volume":"6","author":"Liu","year":"2025","journal-title":"Cell Reports. Medicine"},{"issue":"1","key":"10.1016\/j.intimp.2026.116439_bb0185","doi-asserted-by":"crossref","first-page":"5740","DOI":"10.1038\/s41467-023-41101-3","article-title":"Activation of melanocortin-1 receptor signaling in melanoma cells impairs T cell infiltration to dampen antitumor immunity","volume":"14","author":"Cui","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.intimp.2026.116439_bb0190","doi-asserted-by":"crossref","unstructured":"Wang Yan, Zhao Liang, Luo Jia-Yu, et al. Nanomedicine-mediated co-expression of a PD-1 blockade agent and CXCL9 synergizes T cell infiltration and activation in solid tumors. Biomater. Sci., 2025. 13(22): p. 6410\u20136422.","DOI":"10.1039\/D5BM01105A"},{"key":"10.1016\/j.intimp.2026.116439_bb0195","doi-asserted-by":"crossref","unstructured":"Lim Raymond J., Salehi-Rad Ramin, Tran Linh M., et al. CXCL9\/10-engineered dendritic cells promote T cell activation and enhance immune checkpoint blockade for lung cancer. Cell Reports. Medicine, 2024. 5(4): p. 101479.","DOI":"10.1016\/j.xcrm.2024.101479"},{"issue":"12","key":"10.1016\/j.intimp.2026.116439_bb0200","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1038\/s41423-024-01230-1","article-title":"Kynurenine-AhR reduces T-cell infiltration and induces a delayed T-cell immune response by suppressing the STAT1-CXCL9\/CXCL10 axis in tuberculosis","volume":"21","author":"Liu","year":"2024","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.intimp.2026.116439_bb0205","doi-asserted-by":"crossref","unstructured":"Li Yajun, Chen Kailin, Chen Bihua, et al. Increased coexpression of PD-L1 and IDO1 is associated with poor overall survival in patients with NK\/T-cell lymphoma. Leukemia, 2024. 38(7): p. 1553\u20131563.","DOI":"10.1038\/s41375-024-02266-y"},{"key":"10.1016\/j.intimp.2026.116439_bb0210","doi-asserted-by":"crossref","unstructured":"Shu Guannan, Chen Minyu, Liao Wuyuan, et al. PABPC1L induces IDO1 to promote tryptophan metabolism and immune suppression in renal cell carcinoma. Cancer Res., 2024. 84(10): p. 1659\u20131679.","DOI":"10.1158\/0008-5472.CAN-23-2521"},{"key":"10.1016\/j.intimp.2026.116439_bb0215","doi-asserted-by":"crossref","unstructured":"Qu Xinyu, Wang Yumeng, Jiang Qian, et al. Interactions of Indoleamine 2,3-dioxygenase-expressing LAMP3+ dendritic cells with CD4+ regulatory T cells and CD8+ exhausted T cells: synergistically remodeling of the immunosuppressive microenvironment in cervical cancer and therapeutic implications. Cancer Communications (London, England), 2023. 43(11): p. 1207\u20131228, Cancer Commun.","DOI":"10.1002\/cac2.12486"},{"key":"10.1016\/j.intimp.2026.116439_bb0220","doi-asserted-by":"crossref","unstructured":"Yang Yalan, Li Haifeng, Yang Wei, et al. Improving efficacy of TNBC immunotherapy: based on analysis and subtyping of immune microenvironment. Front. Immunol., 2024. 15: p. 1441667.","DOI":"10.3389\/fimmu.2024.1441667"}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576926002833?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576926002833?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T07:15:02Z","timestamp":1777619702000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576926002833"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":44,"alternative-id":["S1567576926002833"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2026.116439","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CXCL9 as a key feature for deep learning-based immune subtyping and prediction of immune checkpoint blockade response in triple-negative breast cancer","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2026.116439","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"116439"}}